U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07308574) titled 'Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS' on Dec. 17.
Brief Summary: The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic ureminc syndrome (aHUS).
Study Start Date: Dec. 26
Study Type: INTERVENTIONAL
Condition:
aHUS
Atypical Hemolytic Uremic Syndrome
Intervention:
DRUG: Ravulizumab
Participants will receive ravulizumab via IV infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alexion Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Di...